Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.65 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | DPP4 | P27487 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.51 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.48 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11624972 | 0.83 | CYP2A6 (0.60) | CYP2A6CYP2E1CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL27953539 | 0.81 | CYP2A6 (0.54) | CYP2A6CYP2E1CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL9196527 | 0.81 | CYP2A6 (0.54) | CYP2A6CYP2E1CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL8572801 | 0.81 | MEN1 (0.70) | CYP2A6CYP2E1CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL1160546 | 0.79 | ALDH1A1 (0.52) | CYP2A6CYP2E1CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL28280412 | 0.79 | ALDH1A1 (0.52) | CYP2A6CYP2E1CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL2239902 | 0.79 | MEN1 (0.52) | CYP2A6CYP2E1CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL3611935 | 0.79 | CYP2A6 (1.00) | CYP2A6CYP2E1CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL1197836 | 0.79 | CYP2A6 (0.51) | CYP2A6CYP2E1CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL8576605 | 0.79 | DPP4 (0.69) | CYP2A6CYP2E1CYP3A4CYP2C9CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114127066-A | Inhibitors of indoleamine 2, 3-dioxygenase and/or tryptophan 2, 3-dioxygenase | 爱杜西亚药品有限公司 | 2022-03-01 | — | — | CN | disclosed |
| WO-2018058148-A1 | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | TUFTS UNIVERSITY (US) | 2018-03-29 | — | — | WO | disclosed |
| US-8129376-B2 | Piperidine derivatives as inhibitors of stearoyl-CoA desaturase | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-03-06 | — | — | US | disclosed |
| CN-102036558-A | Novel piperidine derivatives as stearoyl-CoA desaturase inhibitors | FOREST LAB HOLDINGS LTD | 2011-04-27 | — | — | CN | disclosed |
| EP-2268143-A2 | NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | Forest Laboratories Holdings Limited (BM) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009117676-A2 | NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | WO | disclosed |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | disclosed |
| US-7342116-B2 | Process for producing heterocyclic aldehyde | KOEI CHEMICAL CO., LTD. (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-06 | — | — | US | disclosed |
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-06 | — | — | US | disclosed |
| US-20050124807-A1 | oxidation of a hetero alcohol in presence od an 2,2,6,6-teraalkylpiperidin-1-oxy comound | KOEI CHEMICAL CO., LTD. (JP) | 2005-06-09 | — | — | US | disclosed |
| US-6096724-A | O(6)-ALKYLGUANINE-DNA ALKYLTRANSFERASE (ATASE) ENZYME INHIBITORS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2000-08-01 | — | — | US | disclosed |
| EP-0874848-A1 | PYRIMIDINE DERIVATIVES AND GUANINE DERIVATIVES, AND THEIR USE IN TREATING TUMOUR CELLS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1998-11-04 | — | — | EP | disclosed |
| WO-1997020843-A1 | PYRIMIDINE DERIVATIVES AND GUANINE DERIVATIVES, AND THEIR USE IN TREATING TUMOUR CELLS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1997-06-12 | — | — | WO | disclosed |
| WO-1993003719-A1 | ARYLALKYLETHER AND ARYLALKYLTHIOETHER INHIBITORS OF LIPOXYGENASE ENZYME ACTIVITY | ABBOTT LABORATORIES (US) | 1993-03-04 | — | — | WO | disclosed |
| US-5183818-A | Also for inhibiting leukotriene biosynthesis | ABBOTT LABORATORIES (US) | 1993-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | GPR119, FFAR1, HCAR1 | CYP2A6 471/4885CYP2E1 1129/4885CYP3A4 761/4885 |
| US-20050124807-A1 | oxidation of a hetero alcohol in presence od an 2,2,6,6-teraalkylpiperidin-1-oxy comound | ADH1C, ADH1A, AOX1 | CYP2A6 69/4885CYP2E1 15/4885CYP3A4 301/4885 |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | SCD, SCD5, FADS2 | CYP2A6 1778/4885CYP2E1 1301/4885CYP3A4 2225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.